Rui-Xia Xu1, Na-Qiong Wu1, Sha Li1, Yan Zhang1, Xiao-Lin Li1, Yuan-Lin Guo1, Cheng-Gang Zhu1, Geng Liu1, Qian Dong1, Jian-Jun Li2. 1. Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China. 2. Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China. lijianjun938@yahoo.com.
Abstract
OBJECTIVE: To investigate the effects of Hedan Tablet () on serum lipid profile, proprotein convertase subtilisin/kexin type 9 (PSCK9) and high-density lipoprotein (HDL) subfractions in patients with hyperlipidemia. METHODS:Thirty-seven patients with hyperlipidemia were randomized to treatment with Hedan Tablet 4.38 g/day as Hedan group (18 cases) or placebo (19 cases) as control group for 8 weeks. The lipid profile, PCSK9 and HDL subfractions were determined at day 0 and week 8 in both groups respectively. RESULTS: Hedan treatment for 8 weeks mildly decreased serum low-density lipoprotein cholesterol (LDL-C) levels, while no changes were found in total cholesterol (TC), triglycerides (TG) and PCSK9 concentrations. Furthermore, Hedan treatment increased the concentration of large high-density lipoprotein cholesterol (HDL-C) and the percentage of large HDL subfraction, while decreased the concentration of small HDL-C and the percentage of small HDL subfraction without changing serum HDL-C levels in patients with hyperlipidemia. CONCLUSION: Hedan treatment of 4.38 g per day for 8 weeks could confer a favorable effects on serum LDL-C concentration as well as HDL subfractions.
RCT Entities:
OBJECTIVE: To investigate the effects of Hedan Tablet () on serum lipid profile, proprotein convertase subtilisin/kexin type 9 (PSCK9) and high-density lipoprotein (HDL) subfractions in patients with hyperlipidemia. METHODS: Thirty-seven patients with hyperlipidemia were randomized to treatment with Hedan Tablet 4.38 g/day as Hedan group (18 cases) or placebo (19 cases) as control group for 8 weeks. The lipid profile, PCSK9 and HDL subfractions were determined at day 0 and week 8 in both groups respectively. RESULTS: Hedan treatment for 8 weeks mildly decreased serum low-density lipoprotein cholesterol (LDL-C) levels, while no changes were found in total cholesterol (TC), triglycerides (TG) and PCSK9 concentrations. Furthermore, Hedan treatment increased the concentration of large high-density lipoprotein cholesterol (HDL-C) and the percentage of large HDL subfraction, while decreased the concentration of small HDL-C and the percentage of small HDL subfraction without changing serum HDL-C levels in patients with hyperlipidemia. CONCLUSION: Hedan treatment of 4.38 g per day for 8 weeks could confer a favorable effects on serum LDL-C concentration as well as HDL subfractions.
Entities:
Keywords:
Chinese medicine; Hedan Tablet; high-density lipoprotein subfraction; hyperlipidemia; lipid profile; proprotein convertase subtilisin/kexin type 9
Authors: H Robert Superko; Lakshmana Pendyala; Paul T Williams; Katherine M Momary; Spencer B King; Brenda C Garrett Journal: J Clin Lipidol Date: 2012-03-23 Impact factor: 4.766
Authors: Greg Welder; Issam Zineh; Michael A Pacanowski; Jason S Troutt; Guoqing Cao; Robert J Konrad Journal: J Lipid Res Date: 2010-06-05 Impact factor: 5.922
Authors: Marcin Barylski; Peter P Toth; Dragana Nikolic; Maciej Banach; Manfredi Rizzo; Giuseppe Montalto Journal: Best Pract Res Clin Endocrinol Metab Date: 2013-11-15 Impact factor: 4.690
Authors: L G Christogiannis; M S Kostapanos; C C Tellis; H J Milionis; A D Tselepis; M S Elisaf Journal: J Hum Hypertens Date: 2011-12-01 Impact factor: 3.012
Authors: Erin D Michos; Christopher T Sibley; Jefferson T Baer; Michael J Blaha; Roger S Blumenthal Journal: J Am Coll Cardiol Date: 2012-04-18 Impact factor: 24.094
Authors: Holly E Careskey; R Aleks Davis; William E Alborn; Jason S Troutt; Guoqing Cao; Robert J Konrad Journal: J Lipid Res Date: 2007-11-21 Impact factor: 5.922